Whitehawk Therapeutics, Inc.

WHWK Healthcare Biotechnology

Whitehawk Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.1 million, down 72.5% from fiscal 2024. In the quarter to June 2026, revenue grew 33.5%, EPS grew 73.7% and free cash flow grew 72.6%, each against the same quarter a year earlier.

2.89 0.15 −4.93%
Market cap
$173.3M
P/E
0.0×
Fwd P/E
−3.2×
Dividend yield
—
F-score
4/9
Altman Z
1.52
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
17.38 11.36 10.26 16.76
Net Debt/EBITDA
10.29 5.16 5.67 8.03
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.18) (0.32) (0.28) (0.22)
Book value per Share
2.21 1.68 2.20 2.27
Free Cash Flow
(14.53) (22.21) (17.23) (15.38)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates